Approved October 2002
Type 2 Diabetes
Diabetes / Endocrinology
Avandamet (rosiglitazone maleate and metformin HCl) has been approved as an adjunct to diet and exercise to improve blood sugar control in type 2 diabetes patients who are already treated with combination rosiglitazone and metformin or who are not adequately controlled on metformin alone.
Avandamet, available in oral tablet formulation, is the first treatment to combine this combination of drugs in one pill.
Clinical studies have been conducted with the combination of rosiglitazone maleate and metformin HCl, as well as with each component alone. These studies have shown that the products are safe and effective in controlling blood sugar levels in type 2 diabetes patients.
No efficacy studies have been conducted for Avandamet tablets. However, Avandamet has been shown to be bioequivalent to co-administered rosiglitazone maleate tablets and metformin hydrochloride tablets.
In clinical trials of rosiglitazone maleate in combination with metformin hydrochloride 2500 mg/day, the following adverse events were reported most frequently:
A small number of people who have been treated with metformin have developed the serious yet rare condition called lactic acidosis (a build up of lactic acid in the blood). Most often, lactic acidosis occurs in people with kidney problems, and it can be fatal.
Rosiglitazone may cause fluid retention, especially if it is used with insulin. Untreated fluid retention could lead to or worsen heart failure.
Avandamet should not be used with insulin, and should not be used by patients with kidney disease, congestive heart failure, or liver disease.
Rosiglitazone maleate is a member of the thiazolidinedione class of antidiabetic agents and is a PPARgamma agonist. It improves glycemic control by improving insulin sensitivity while reducing circulating insulin levels.
Metformin hydrochloride is a member of the biguanide class of antidiabetic agents. It decreases hepatic glucose production, decreases intestinal absorption of glucose, and increases peripheral glucose uptake and utilization. Unlike sulfonylureas, metformin does not produce hypoglycemia in either patients with type 2 diabetes or normal subjects and does not cause hyperinsulinemia. With metformin therapy, insulin secretion remains unchanged, while fasting insulin levels and day-long plasma insulin response may actually decrease. (from FDA prescription label)
For more information about Avandamet, please visit the GlaxoSmithKline web site at www.gsk.com.
The Avandamet drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.